Keyword Tag Sort by

Carcinoid News (1 article)

Phase III Novartis data show potential benefit of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumors

Everolimus plus octreotide LAR extended time without tumor growth from 11.3 to 16.4 months versus octreotide LAR alone in advanced NET (carcinoid) patients[1] The study did not reach its primary endpoint of progression-free survival[1] Analyses to adjust for imbalances in...

Published on 11 October 2010, 08:28